Polidocanol 1% and Steroid in Keloids and Hypertrophic Scars

Starting soon · Not applicable

Conditions studied: Keloid and Hypertrophic Scars

In brief

we will inject intralesional polidocanol 1% in keloids and hypertrophic scars to decrease vascularity and decrease size of lesion compared to intralesional steroid as standard treatment line

Key facts

Study ID

NCT07606391

Run by

Sohag University

People needed

90

Starts

2026-08-01

Expected to finish

2027-08-01

Last updated by the study team

2026-05-26

Who can join

Age: 16 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients older than 16 years of both sex with keloids and/or hypertrophic scars ≤ year.

You may not qualify if…

• Pregnancy, lactation.
• Skin lesions, infection in the injection area.
• Patients with systemic disease (diabetes mellitus, heart disease, cancer, mental illness).
• Allergy to substances used.
• Patients received treatment in previous 4 weeks.
• Current anticoagulant therapy.
• Active thromboembolic disease, use of oral contraceptives or other drugs affecting coagulation cascade.
• History of venous or arterial thromboembolism.
• Severe renal dysfunction.

Where it is running

• Sohag University — Sohag, Egypt

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.